Mucosal adjuvants

Mucosal Immunology, Two-Volume Set

Volumn , Issue , 2005, Pages 967-986

  Elson, Charles O ^a   Dertzbaugh, Mark T ^b  

^a University of Alabama at Birmingham   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33644842604     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012491543-5/50058-9     Document Type: Chapter

References (224)

1. Abraham E., Robinson A. Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia. Vaccine 1991, 9:757-764.
2. Alisky J.M., van de Wetering C.I., Davidson B.L. Widespread dispersal of cholera toxin subunit B to brain and spinal cord neurons following systemic delivery. Exp. Neurol. 2002, 178:13-46.
3. Anastassiou E.D., Yamada H., Boumpas D.T., Tsokos G.C., Thyphronitis G., Balow J., Mond J.J. Cholera toxin promotes the proliferation of anti-mu antibody-prestimulated human B cells. Cell. Immunol. 1992, 140:237-247.
4. Araneo B., Dowell T., Woods M.L., Daynes R., Judd M., Evans T. DHEAS as an effective vaccine adjuvant in elderly humans: Proof-of-principle studies. Ann. N.Y. Acad. Sci. 1995, 774:232-248.
5. Araneo B., Kreisel J., Ricigliano J., Norton S. Vitamin D3-enhanced protection in two murine models of viral infection: influenza and herpes simplex 2. Clin. Immunol. Immunopathol. 1995, 76:S122.
6. Araneo B., Kreisel J., Ricigliano J., Norton S. Vitamin D3-enhanced protection in two murine models of viral infection: influenza and herpes simplex 2. Clin. Immunol. Immunopathol. 1995, 76:A718.
7. Bazin H., Platteau B. Production of circulating reaginic (IgE) antibodies by oral administration of ovalbumin to rats. Immunology 1976, 30:679-684.
8. Bergmann K.C., Waldman R.H. Enhanced murine respiratory tract IgA antibody response to oral influenza vaccine when combined with a lipoidal amine (Avridine). Int. Arch. Allergy. Appl. Immunol. 1988, 87:334-335.
9. Bergquist C., Lagergard T., Lindblad M., Holmgren J. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect. Immun. 1995, 63:2021-2025.
10. Bessen D., Fischetti V.A. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect. Immun. 1988, 56:2666-2672.
11. Betley M., Miller V., Mekalanos J. Genetics of bacterial enterotoxins. Annu. Rev. Microbiol. 1986, 40:577-605.
12. Bland P.W., Warren L.G. Antigen presentation by epithelial cells of the rat small intestine. II. Selective induction of suppressor cells. Immunology 1986, 58:9-14.
13. Bost K.L., Holton R.H., Clements J.D. In vivo treatment with antibodies against IL-13 dramatically inhibits mucosal and systemic humoral responses in mice orally immunized with the B subunit of E. coli heat labile enterotoxin. Clin. Immunol. Immunopathol. 1995, 76:S122.
14. Bost K.L., Holton R.H., Clements J.D. In vivo treatment with antibodies against IL-13 dramatically inhibits mucosal and systemic humoral responses in mice orally immunized with the B subunit of E. coli heat labile enterotoxin. Clin. Immunol. Immunopathol. 1995, 76:A719.
15. Bourguin I., Chardes T., Mevelec M.N., Woodman J.P., Bout D. Amplification of the secretory IgA response to Toxoplasma gondii using cholera toxin. FEMS Microbiol. Lett. 1991, 65:265-271.
16. Bowen J.C., Nair S.K., Reddy R., Rouse B.T. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with nonreplicating antigens. Immunology 1994, 81:338-342.
17. Boyaka P.N., Marinaro M., Jackson R.J., Menon S., Kiyono H., Jirillo E., McGhee J.R. IL-12 is an effective adjuvant for induction of mucosal immunity. J. Immunol. 1999, 162:122-128.
18. Boyaka P.N., Ohmura M., Fujihashi K., Koga T., Yamamoto M., Kweon M.N., Takeda Y., Jackson R.J., Kiyono H., Yuki Y., McGhee J.R. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. J. Immunol. 2003, 170:454-462.
19. Braun M.C., He J., Wu C.Y., Kelsall B.L. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor a1 and a2 chain expression. J. Exp. Med. 1999, 189:541-552.
20. Brey R.N. Development of vaccines based on formulations containing nonionic block copolymers. Pharm. Biotechnol. 1995, 6:297-311.
21. Bromander A., Holmgren J., Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 1991, 146:2908-2914.
22. Bromander A.K., Ekman L., Kopf M., Nedrud J.G., Lycke N.Y. IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection. J. Immunol. 1996, 156:4290-4297.
23. Bromander A.K., Kjerrulf M., Holmgren J., Lycke N. Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand. J. Immunol. 1993, 37:452-458.
24. Bukawa H., Sekigawa K., Hamajima K., Fukushima J., Yamada Y., Kiyono H., Okuda K. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nature Med. 1995, 1:681-685.
25. Castello-Branco L.R., Griffin G.E., Poulton T.A., Dougan G., Lewis D.J. Characterization of the circulating T-cell response after oral immunization of human volunteers with cholera toxin B subunit. Vaccine 1994, 12:65-72.
26. Cavanagh N.P., Brett E.M., Marshall W.C., Wilson J. The possible adjuvant role of Bordetella pertussis and pertussis vaccine in causing severe encephalopathic illness: A presentation of three case histories. Neuropediatrics 1981, 12:374-381.
27. Chen K.S., Strober W. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: Disproportionate cholera toxin enhancement of the IgA B cell response. Eur. J. Immunol. 1990, 20:433-436.
28. Chiller J.M., Skidmore B.J., Morrison D.C., Weigle W.O. Relationship of the structure of bacterial lipopolysaccharides to its function in mitogenesis and adjuvanticity. Proc. Natl. Acad. Sci. USA 1973, 70:2129-2135.
29. Clarke C.J., Wilson A.D., Williams N.A., Stokes C.R. Mucosal priming of T-lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant. Immunology 1991, 72:323-328.
30. Clements J.D., Hartzog N.M., Lyon F.L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988, 6:269-277.
31. Cong Y., Bowdon H.R., Elson C.O. Identification of an immunodominant T cell epitope on cholera toxin. Eur. J. Immunol. 1996, 26:2587-2594.
32. Cong Y., Weaver C.T., Elson C.O. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 1977, 159:5301-5308.
33. Cong Y., Oliver A.O., Elson C.O. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. Eur. J. Immunol. 2001, 31:64-71.
34. Cowdery J.S., Chace J.H., Yi A.K., Krieg A.M. Bacterial DNA induces NK cells to produce IFN-. in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 1996, 156:4570-4575.
35. Crowe S.E., Sestini P., Perdue M.H. Allergic reactions of rat jejunal mucosa: Ion transport responses to luminal antigen and inflammatory mediators. Gastroenterology 1990, 99:74-82.
36. Cuatrecasas P. Gangliosides and membrane receptors for cholera toxin. Biochemistry 1973, 12:3556-3558.
37. Czerkinsky C., Russell M.W., Lycke N., Lindblad M., Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect. Immun. 1989, 57:1072-1077.
38. Czerkinsky C., Svennerholm A.M., Quiding M., Jonsson R., Holmgren J. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect. Immun. 1991, 59:996-1001.
39. Czinn S.J., Nedrud J.G. Oral immunization against Helicobacter pylori. Infect. Immun. 1991, 59:2359-2363.
40. Dalsgaard K. Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in foot-and-mouth disease vaccines. Arch. Gesamte. Virusforsch. 1974, 44:243-254.
41. Daynes R.A., Enioutina E.Y., Butler S., Mu H.H., McGee Z.A., Araneo B.A. Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization. Infect. Immun. 1996, 64:1100-1109.
42. De Bernardis F., Boccanera M., Adriani D., Girolamo A., Cassone A. Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect. Immun. 2002, 70:2725-2729.
43. Dertzbaugh M.T., Elson C.O. Cholera toxin as a mucosal adjuvant. Topics in Vaccine Adjuvant Research 1991, 119-131. CRC Press, Boca Raton, FL. D.R. Spriggs, W.C. Koff (Eds.).
44. Dertzbaugh M.T., Elson C.O. Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect. Immun. 1993, 61:48-55.
45. Dertzbaugh M.T., Elson C.O. Reduction in oral immunogenicity of cholera toxin B subunit by N-terminal peptide addition. Infect. Immun. 1993, 61:384-390.
46. Dertzbaugh M.T., Peterson D.L., Macrina F.L. Cholera toxin B subunit gene fusion: Structural and functional analysis of the chimera protein. Infect. Immun. 1990, 58:70-79.
47. Douce G., Turcotte C., Cropley I., Roberts M., Pizza M., Domenghini M., Rappuoli R., Dougan G. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as non-toxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 1995, 92:1644-1648.
48. Elson C.O. Cholera toxin as a mucosal adjuvant: Effects of H-2 major histocompatibility complex and lps genes. Infect. Immun. 1992, 60:2874-2879.
49. Elson C.O., Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol. 1984, 133:2892-2897.
50. Elson C.O., Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 1984, 132:2736-2742.
51. Elson C.O., Ealding W. Ir gene control of the murine secretory IgA response to cholera toxin. Eur. J. Immunol. 1987, 17:425-428.
52. Elson C.O., Holland S.P., Dertzbaugh M.T., Cuff C.F., Anderson A.O. Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. J. Immunol. 1995, 154:1032-1040.
53. Elson C.O., Tomasi M., Chang T.-T., Jobling M.G., Holmes R.K. Immunogenicity and adjuvanticity of mutant cholera toxin (CT) molecules. FASEB J. 1995, 9:A290.
54. Elson C.O., Tomasi M., Dertzbaugh M.T., Thaggard G., Hunter R., Weaver C. Oral-antigen delivery by way of a multiple emulsion system enhances oral tolerance. Ann. N.Y. Acad. Sci. 1996, 778:156-162.
55. Finkelman F.D., Holmes J., Katona I.M., Urban J.F.J., Beckmann M.P., Park L.S., Schooley K.A., Coffman R.L., Mosmann T.R., Paul W.E. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 1990, 8:303-333.
56. Fossum C., Bergstrom M., Lovgren K., Watson D.L., Morein B. Effect of ISCOMs and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: Comparison of spleen cells from mice inoculated with ISCOMs and/or matrix. Cell. Immunol. 1990, 129:414-425.
57. Francis M.L., Ryan J., Jobling M.G., Holmes R.K., Moss J., Mond J.J. Cyclic AMP-independent effects of cholera toxin on B cell activation. II. Binding of ganglioside GM1 induces B cell activation. J. Immunol. 1992, 148:1999-2005.
58. Fraser S.A., de Haan L., Hearn A.R., Bone H.K., Salmond R.J., Rivett A.J., Williams N.A., Hirst T.R. Mutant Escherichia coli heat-labile toxin B subunit that separates toxoidmediated signaling and immunomodulatory action from trafficking and delivery functions. Infect. Immun. 2003, 71:1527-1537.
59. Frey A., Giannasca K.T., Weltzin R., Giannasca P.J., Reggio H., Lencer W.I., Neutra M.R. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: Implications for microbial attachment and oral vaccine targeting. J. Exp. Med. 1996, 184:1045-1059.
60. Gizurarson S., Tamura S., Aizawa C., Kurata T. Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit. Vaccine 1992, 10:101-106.
61. Grdic D., Hornquist E., Kjerrulf M., Lycke N.Y. Lack of local suppression in orally tolerant CD8-deficient mice reveals a critical regulatory role of CD8+ T cells in the normal gut mucosa. J. Immunol. 1998, 160:754-762.
62. Hajishengallis G., Hollingshead S.K., Koga T., Russell M.W. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J. Immunol. 1995, 154:4322-4332.
63. Hajishengallis G., Michalek S.M., Russell M.W. Persistence of serum and salivary antibody responses after oral immunization with a bacterial protein antigen genetically linked to the A2/B subunits of cholera toxin. Infect. Immun. 1996, 64:665-667.
64. Hansson H.A., Lange S., Lonnroth I. Internalization in vivo of cholera toxin in the small intestinal epithelium of the rat. Acta Pathol. Microbiol. Immunol. Scand. [A] 1984, 92:15-21.
65. Hearn T.I. Murine Mucosal and Systemic Immune Responses to Antigens Delivered by Oral Infusion in Water-in-Oil-in-Water Emulsions Containing Block Copolymer P1005. Ph.D. thesis. Atlanta: Emory University 1995.
66. Heinevetter L., Baier W., Wiesmuller H.H., Jung G., Bessler W.G. Synthetic lipopeptides as adjuvants in oral immunization. Clin. Immunol. Immunopathol. 1995, 76:S18.
67. Herzenberg L.A., Tokuhisa T. Epitope-specific regulation I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J. Exp. Med. 1982, 155:1730-1740.
68. Hirabayashi Y., Tamura S.I., Suzuki Y., Nagamine T., Aizawa C., Shimada K., Kurata T. H-2-unrestricted adjuvant effect of cholera toxin B subunit on murine antibody responses to influenza virus haemagglutinin. Immunology 1991, 72:329-335.
69. Hol W.G.J., Sixma T.K., Meritt E.A. Structure and function of E. coli heat-labile enterotoxin and cholera toxin B pentamer. Bacterial Toxins and Virulence Factors in Disease 1995, 185-223. Marcel Dekker, New York. J. Moss, B. Iglewski, M. Vaughan, A.T. Tu (Eds.).
70. Hooper C. The new age of vaccine adjuvants. J. NIH Res. 1991, 3:21-23.
71. Hordnes K., Digranes A., Haugen I.L., Helland D.E., Ulstein M., Jonsson R., Haneberg B. Systemic and mucosal antibody responses to group B streptococci following immunization of the colonic rectal mucosa. J. Reprod. Immunol. 1995, 28:247-262.
72. Hornquist E., Lycke N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 1993, 23:2136-2143.
73. + T cell dependent. Infect. Immun. 1991, 59:3630-3638.
74. Hornquist E., Grdic D., Mak T., Lycke N. CD8-deficient mice exhibit augmented mucosal immune responses and intact adjuvant effects to cholera toxin. Immunology 1996, 87:220-229.
75. Hoshi S., Nakamura T., Nunoya T., Ueda S. Induction of protective immunity in chickens orally immunized with inactivated infectious bursal disease virus. Vaccine 1995, 13:245-252.
76. Hui G.S.N., Chang S.P., Gibson H., Hashimoto A., Hashiro C., Barr P.J., Kotani S. Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195. J. Immunol. 1991, 147:3935-3941.
77. Hunter R.L., McNicholl J., Lal A.A. Mechanisms of action of nonionic block copolymer adjuvants. AIDS Res. Hum. Retroviruses 1994, 10:S95-S98.
78. Imaoka K., Miller C.J., Kubota M., McChesney M.B., Lohman B., Yamamoto M., Fuhihashi K., Someya K., Honda M., McGhee J.R., Kiyono H. Nasal immunization of nonhuman primates with simian immunodeficiency virus P55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J. Immunol. 1998, 161:5952-5958.
79. Jackson R.J., Fujihashi K., Xu-Amano J., Kiyono H., Elson C.O., McGhee J.R. Optimizing oral vaccines: Induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect. Immun. 1993, 61:4272-4279.
80. Jarrett E.E., Haig D.M., McDougall W., McNulty E. Rat IgE production. II. Primary and booster reaginic antibody responses following intradermal or oral immunization. Immunology 1976, 30:671-677.
81. Jertborn M., Svennerholm A.M., Holmgren J. Five-year immunologic memory in Swedish volunteers after oral cholera vaccination. J. Infect. Dis. 1988, 157:374-377.
82. Jeurissen S.H., Sminia T., Beuvery E.C. Induction of mucosal immunoglobulin A immune response by preparations of Neisseria gonorrhoeae porin proteins. Infect. Immun. 1987, 55:253-257.
83. Jobling M.G., Holmes R.K. Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis. Mol. Microbiol. 1991, 5:1755-1767.
84. Jobling M.G., Holmes R.K. Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxinlike chimeras. Infect. Immun. 1992, 60:4915-4924.
85. Johnson A.J., Gaines S., Landy M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of the antibody response to protein antigens by the purified lipopolysaccharide. J. Exp. Med. 1956, 103:225-233.
86. Justewicz D.M., Morin M.J., Robinson H.L., Webster R.G. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. J. Virol. 1995, 69:7712-7717.
87. Kang S.M., Compans R.W. Enhancement of immunization with virus-like particles of simian immunodeficiency virus. J. Virol. 2003, 77:3615-3623.
88. Kay R.A., Ferguson A. The immunological consequences of feeding cholera toxin. I. Feeding cholera toxin suppresses the induction of systemic delayed-type hypersensitivity but not humoral immunity. Immunology 1989, 66:410-415.
89. Kay R.A., Ferguson A. The immunological consequences of feeding cholera toxin. II. Mechanisms responsible for the induction of oral tolerance for DTH. Immunology 1989, 66:416-421.
90. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 1991, 146:431-437.
91. Keren D.F., McDonald R.A., Carey J.L. Combined parenteral and oral immunization results in an enhanced mucosal immunoglobulin A response to Shigella flexneri. Infect. Immun. 1988, 56:910-915.
92. Khoury S.J., Lider O., Al-Sabbagh A., Weiner H.L. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. Cell. Immunol. 1990, 131:302-310.
93. Klimpel G.R., Asuncion M., Haithcoat J., Niesel D.W. Cholera toxin and Salmonella typhimurium induce different cytokine profiles in the gastrointestinal tract. Infect. Immun. 1995, 63:1134-1137.
94. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon-α. Proc. Natl. Acad. Sci. USA 1996, 93:2879-2883.
95. Kuper C.F., Koornstra P.J., Hameleers D.M., Biewenga J., Spit B.J., Duijvestijn A.M., van Breda Vriesman P.J.C., Sminia T. The role of nasopharyngeal lymphoid tissue. Immunol. Today 1992, 13:219-224.
96. Kuznecov A.W., Cohen N., Moynihan J. Adjuvant effects of freely ingested cholera toxin on systemic antibody and DTH responses to protein antigen. Reg. Immunol. 1992, 4:153-161.
97. Kweon M.N., Yamamoto M., Watanabe F., Tamura S., Van Ginkel F.W., Miyauchi A., Takagi H., Takeda Y., Hamabata T., Fujihashi K., McGhee J.R., Kiyono H. A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J. Infect. Dis. 2002, 186:1261-1269.
98. Lebman D.A., Fuhrman J.A., Cebra J.J. Itraduodenal application of cholera holotoxin increases the potential of clones from Peyer's patch B cells of relevant and unrelated specificities to secrete IgG and IgA. Reg. Immunol. 1988, 1:32-40.
99. Lee A., Chen M. Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect. Immun. 1994, 62:3594-3597.
100. Lencer W.I., de Almeida J.B., Moe S., Stow J.L., Ausiello D.A., Madara J.L. Entry of cholera toxin into polarized human intestinal epithelial cells: Identification of an early brefeldin A sensitive event required for A1-peptide generation. J. Clin. Invest. 1993, 92:2941-2951.
101. Levine M.M., Kaper J.B., Black R.E., Clements M.L. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 1983, 47:510-550.
102. Lewis D.J., Castello B.L.R., Novotny P., Dougan G., Poulton T.A., Griffin G.E. Circulating cellular immune response to oral immunization of humans with cholera toxin B-subunit. Vaccine 1993, 11:119-121.
103. Liang X., Lamm M.E., Nedrud J.G. Cholera toxin as a mucosal adjuvant: Glutaraldehyde treatment dissociates adjuvanticity from toxicity. J. Immunol. 1989, 143:484-490.
104. Liang X.P., Lamm M.E., Nedrud J.G. Cholera toxin as a mucosal adjuvant for respiratory antibody responses in mice. Reg. Immunol. 1989, 2:244-248.
105. Lovgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand. J. Immunol. 1988, 27:241-245.
106. Lowell G.H., Ballou W.R., Smith L.F., Wirtz R.A., Zollinger W.D., Hockmeyer W.T. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria. CS peptides. Science 1988, 240:800-803.
107. Lowell G.H., Kaminski R.W., Grate S., Hunt R.E., Charney C., Zimmer S., Colleton C. Intranasal and intramuscular proteasome-staphylococcal enterotoxin B (SEB) toxoid vaccines: Immunogenicity and efficacy against lethal SEB intoxication in mice. Infect. Immun. 1996, 64:1706-1713.
108. Lu X., Clements J.D., Katz J.M. Mutant Escherichia coli-heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 2002, 20:7-8.
109. Lycke N., Bromander A.K., Ekman L., Karlsson U., Holmgren J. Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo. J. Immunol. 1989, 142:20-27.
110. Lycke N., Hellstrom U., Holmgren J. Circulating cholera antitoxin memory cells in the blood one year after oral cholera vaccination in humans. Scand. J. Immunol. 1987, 26:207-211.
111. Lycke N., Holmgren J. Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunization with cholera toxin. Scand. J. Immunol. 1986, 23:611-616.
112. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986, 59:301-308.
113. Lycke N., Holmgren J. Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization. Scand. J. Immunol. 1987, 25:407.
114. Lycke N., Karlsson U., Sjolander A., Magnusson K.E. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand. J. Immunol. 1991, 33:691-698.
115. 1 switch differentiation. J. Immunol. 1990, 145:3316.
116. Lycke N., Strober W. Cholera toxin promotes B cell isotype differentiation. J. Immunol. 1989, 142:3781-3787.
117. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 1992, 22:2277-2281.
118. Lycke N.Y. Cholera toxin promotes B cell isotype switching by two different mechanisms: cAMP induction augments germ-line Ig H-chain RNA transcripts whereas membrane ganglioside GM1-receptor binding enhances later events in differentiation. J. Immunol. 1993, 150:4810-4821.
119. Lycke N. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses. Curr. Opin. Mol. Ther. 2001, 3:37-44. (2001).
120. Malley R., Lipsitch M., Stack A., Saladino R., Fleisher G., Pelton S., Thompson C., Briles D., Anderson P. Intransasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect. Immun. 2001, 69:4870-4873.
121. Marinaro M., Boyaka P.N., Jackson R.J., Finkelman F.D., Kiyono H., McGhee J.R. Interleukin-12 alters helper T-cell subsets and antibody profiles induced by the mucosal adjuvant cholera toxin. Ann. N. Y. Acad. Sci. 1996, 795:361-365.
122. Marinaro M., Boyaka P.N., Jackson R.J., Finkelman F.D., Kiyono H., Jirillo E., McGhee J.R. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J. Immunol. 1999, 162:114-121.
123. Matousek M.P., Nedrud J.G., Harding C.V. Distinct effects of recombinant cholera toxin B subunit and holotoxin on different stages of class II MHC antigen processing and presentation by macrophages. J. Immunol. 1996, 156:4137-4145.
124. Mayer L., Eisenhardt D., Shlien R. Selective induction of antigen nonspecific suppressor cells with normal gut epithelium as accessory cells. Monogr. Allergy 1988, 24:78-80.
125. McCluskie M.J., Weeratna R.d., Payette P.J., Davis H.L. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol. Med. Microbiol. 2002, 32:179-185.
126. McGee D.W., Beagley K.W., Aicher W.K., McGhee J.R. Transforming growth factor-β and IL-1β act in synergy to enhance IL-6 secretion by the intestinal epithelial cell line, IEC-6. J. Immunol. 1993, 151:970-978.
127. McGee D.W., Elson C.O., McGhee J.R. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: Mode of action and augmenting effect of inflammatory cytokines. Infect. Immun. 1993, 61:4637-4644.
128. McKenzie S.J., Halsey J.F. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J. Immunol. 1984, 133:1818-1824.
129. Merritt E.A., Sarfaty S., van den Akker F., L'Hoir C., Martial J.A., Hol W.G. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 1994, 3:166-175.
130. Merritt E.A., Sixma T.K., Kalk K.H., Van Zanten B.A.M., Hol W.G.J. Galactose binding site in E. coli heat-labile enterotoxin (LT) and cholera toxin (CT). Mol. Microbiol. 1994, 13:745-753.
131. Michalek S.M., McGhee J.R., Kiyono H., Colwell D.E., Eldridge J.H., Wannemuehler M.J., Koopman W.J. The IgA response: Inductive aspects, regulatory cells, and effector functions. Ann. N. Y. Acad. Sci. 1983, 409:48-69.
132. Michel F.B., Dussourd D.H.L., Bousquet J., Pinel A.M., Normier G. Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans. Infect. Immun. 1978, 20:760-769.
133. Michetti P., Kreiss C., Kotloff K., Porta N., Blanco J.L., Bachmann D., Saldinger P.F., Corthesy-Theulaz I., Losonsky G., Nichols R., Herranz M., et al. Oral immunization with urease and Escherichia coli heat-labile endotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999, 116:804-812.
134. Mitchell G.F., Munoz J.J. Vaccination of genetically susceptible mice against chronic infection with Nematospiroides dubius using pertussigen as adjuvant. Aust. J. Exp. Biol. Med. Sci. 1983, 61:425-434.
135. Mizoguchi K., Nakashima I., Hasegawa Y., Isobe K., Nagase F., Kawashima K., Shimokata K., Kato N. Augmentation of antibody responses of mice to inhaled protein antigens by simultaneously inhaled bacterial lipopolysaccharides. Immunobiology 1986, 173:63-71.
136. Morasaki I., Michalek S.M., Harmon C.C., Torii M., Hamada S., McGhee J.R. Effective immunity to dental caries: Enhancement of salivary anti-Streptococcus mutans antibody responses with oral adjuvants. Infect. Immun. 1983, 40:577-591.
137. Morein B. Potentiation of the immune response by immunization with antigens in defined multimeric physical forms. Vet. Immunol. Immunopathol. 1987, 17:153-159.
138. Morein B., Fossum C., Lovgren K., Hoglund S. The ISCOM-A modern approach to vaccines. Virology 1990, 1:49-55.
139. Mosmann T.R., Coffman R.L. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989, 7:145-147.
140. Mowat A.M., Donachie A.M., Reid G., Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 1991, 72:317-322.
141. Mowat A.M., Thomas M.J., MacKenzie S., Parrott D.M. Divergent effects of bacterial lipopolysaccharide on immunity to orally administered protein and particulate antigens in mice. Immunology 1986, 58:677-683.
142. Mowat A.M., Donachie A.M., Jagewall S., Schon K., Lowenadler B., Dalsgaard K., Kaastrup P., Lycke N. CTA1-DD-immune stimulating complexes: a novel, rationally designed, combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J. Immunol. 2001, 167:3398-3405.
143. Muller C.P., Beauverger P., Schneider F., Jung G., Brons N.H. Cholera toxin B stimulates systemic neutralizing antibodies after intransal coimmunization with measles virus. J. Gen. Virol. 1995, 76:1371-1380.
144. Murray M., Robinson P.B., Grierson C., Crawford R.A. Immunization against Nippostrongylus brasiliensis in the rat: A study on the use of antigen extracted from adult parasites and the parameters which influence the level of protection. Acta Trop. 1979, 36:297-322.
145. Murray P.D., McKenzie D.T., Swain S.L., Kagnoff M.F. Interleukin 5 and interleukin 4 produced by Peyer's patch T cells selectively enhance immunoglobulin A expression. J. Immunol. 1987, 139:2669-2674.
146. Nagy B., Hoglund S., Morein B. ISCOM (immunostimulating complex) vaccines containing mono- or polyvalent pili of enterotoxigenic E. coli: Immune response of rabbit and swine. Zentralbl. Veterinarmed. [B] 1990, 37:728-738.
147. Nashar T.O., Hirst T.R. Immunoregulatory role of H-2 and intra-H-2 alleles on antibody responses to recombinant preparations of B-subunits of Escherichia coli heat-labile enterotoxin (rEtxB) and cholera toxin (rCtxB). Vaccine 1995, 13:803-810.
148. Nedrud J.G., Sigmund N. Cholera toxin as a mucosal adjuvant. III. Antibody responses to nontarget dietary antigens are not increased. Reg. Immunol. 1991, 3:217-222.
149. Nedrud J.G., Liang X.P., Hague N., Lamm M.E. Combined oral/nasal immunization protects mice from Sendai virus infection. J. Immunol. 1987, 139:3484-3492.
150. Ogawa T., Kotani S., Shimauchi H. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin. Methods Final. Exp. Clin. Pharmacol. 1986, 8:19-26.
151. Ohta M., Nakashima I., Kato N. Adjuvant action of bacterial lipopolysaccharide in induction of delayed-type hypersensitivity to protein antigens. II. Relationships of intensity of the action to that of other immunological activities. Immunobiology 1982, 163:460-466.
152. Oien N.L., Brideau R.J., Walsh E.E., Wathen M.W. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine 1994, 12:731-735.
153. + Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect. Immun. 1996, 64:1516-1525.
154. Okutomi T., Inagawa H., Nishizawa T., Oshima H., Soma G., Mizuno D. Priming effect of orally administered muramyl dipeptide on induction of exogenous tumor necrosis factor. J. Biol. Resp. Med. 1990, 9:564-569.
155. O'Neal C.M., Clements J.D., Estes M.K., Conner M.E. Rotavirus 2/6 virus-like particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J. Virol. 1998, 72:3390-3393.
156. Orr N., Arnon R., Rubin G., Cohen D., Bercovier H., Lowell G.H. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intransal proteosome-Shigella flexneri 2a LPS vaccines. Infect. Immun. 1994, 62:5198-5200.
157. Parant M., Parant F., Chedid L. Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc. Natl. Acad. Sci. USA 1978, 75:3395-3399.
158. Park E.J., Chang J.H., Kim J.S., Chung S.I. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heatlabile enterotoxin varies with immunization routes. Exp. Mol. Med. 2000, 32:72-78.
159. Periwal S.B., Kourie K.R., Ramachandaran N., Blakeney S.J., DeBruin S., Zhu D., Zamb T.J., Smith L., Udem S., Eldridge J.H., Shroff K.E., Reilly P.A. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine. Vaccine 2003, 21:376-385.
160. Pierce N.F., Cray W.C. Determinants of the localization, magnitude, and duration of a specific mucosal IgA plasma cell response in enterically immunized rats. J. Immunol. 1982, 128:1311-1315.
161. Pierce N.F., Gowans J.L. Cellular kinetics of the intestinal immune response to cholera toxoid in rats. J. Exp. Med. 1975, 142:1550-1563.
162. Porgador A., Staats H.F., Itoh Y., Kelsall B.L. Intransal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. Infect. Immun. 1998, 66:5876-5881.
163. Quiding M., Nordstrom I., Kilander A., Andersson G., Hanson L.A., Holmgren J., Czerkinsky C. Intestinal immune responses in humans: Oral cholera vaccination induces strong intestinal antibody responses and interferon-γ production and evokes local immunological memory. J. Clin. Invest. 1991, 88:143-148.
164. Ramsay A.J., Husband A.J., Ramshaw I.A., Bao S., Matthaei K.I., Koehler G., Kopf M. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994, 264:561-563.
165. Rehmani S.F., Spradbrow P.B. The influence of adjuvants on oral vaccination of chickens against Newcastle disease. Vet. Microbiol. 1995, 46:63-68.
166. Rescigno M., Urbano M., Valzasina B., Francolini M., Rotta G., Bonasio R., Granucci F., Kraehenbuhl J.P., Ricciardi-Castagnoli P. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2001, 2:361-367.
167. Reuman P.D., Keely S.P., Schiff G.M. Similar subclass antibody responses after intransal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV. J. Med. Virol. 1991, 35:192-197.
168. Robert D., Quillon J.P., Ivanoff B., Beaudry Y., Fontanges R., Normier G., Pinel A.M., D'Hinterland L.D. Role of interferon in mice in protection against influenza A virus by bacterial ribosomes together with membranal glycoproteins of Klebsiella pneumoniae as adjuvant. Infect. Immun. 1979, 26:515-519.
169. Roberts M., Bacon A., Rappuoli R., Pizza M., Cropley I., Douce G., Dougan G., Marinaro M., McGhee J., Chatfield S. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect. Immun. 1995, 63:2100-2108.
170. Russell M.W., Moldoveanu Z., White P.L., Sibert G.J., Mestecky J., Michalek S.M. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect. Immun. 1996, 64:1272-1283.
171. Sanchez J., Svennerholm A.M., Holmgren J. Genetic fusion of a nontoxic heat-stable enterotoxin-related decapeptide antigen to cholera toxin B-subunit. FEBS Lett. 1988, 241:110-114.
172. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M., Silverman G.J., Lotz M., Carson D.A., Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273:352-354.
173. Shreedhar V.K., Kelsall B.L., Neutra M.R. Cholera toxin induces migration of dendritic cells from the subepithelial dome region to T- and B-cell areas of Peyer's patches. Infect. Immun. 2003, 71:504-509.
174. Simmons C.P., Mastroeni P., Fowler R., Ghaem-maghami M., Lycke N., Pizza M., Rappuoli R., Dougan G. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J. Immunol. 1999, 163:6502-6510.
175. Sixma T.K., Pronk S.E., Kalk K.H., Wartna E.S., van Zanten B.A.M., Witholt B., Hol W.G. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature 1991, 351:371-377.
176. Snapper C.M., Paul W.E. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987, 236:944-947.
177. Snider D.P., Marshall J.S., Perdue M.H., Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J. Immunol. 1994, 153:647-657.
178. Topics in Vaccine Adjuvant Research 1991, CRC Press, Boca Raton, FL. D.R. Spriggs, W.C. Koff (Eds.).
179. Suckow M.A., Keren D.F., Brown J.E., Keusch G.T. Stimulation of gastrointestinal antibody to Shiga toxin by orogastric immunization in mice. Immunol. Cell. Biol. 1994, 72:69-74.
180. Sun J.B., Holmgren J., Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. USA 1994, 91:10795-10799.
181. Sun J.B., Rask C., Olsson T., Holmgren J., Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl. Acad. Sci. USA 1996, 93:7196-7201.
182. Svennerholm A.M., Jertborn M., Gothefors L., Karim A.M.M.M., Sack D.A., Holmgren J. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J. Infect. Dis. 1984, 149:884-893.
183. Takada H., Kotani S. Structural requirements of lipid A for endotoxicity and other biological activities. Crit. Rev. Microbiol. 1989, 16:477-523.
184. Takahashi H., Takeshita T., Morein B., Putney S., Germain R.N., Berzofsky J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990, 344:873-875.
185. Takahashi I., Marinaro M., Kiyono H., Jackson R.J., Nakagawa I., Fujihashi K., Hamada S., Clements J.D., Bost K.L., McGhee J.R. Mechanisms for mucosal immunogenicity and adjuvanticity of Escherichia coli labile enterotoxin. J. Infect. Dis. 1996, 173:627-635.
186. Takahashi I., Okahashi N., Kanamoto T., Asakawa H., Koga T. Intranasal immunization of mice with recombinant protein antigen of serotype c Streptococcus mutans and cholera toxin B subunit. Arch. Oral. Biol. 1990, 35:475-477.
187. Takayama K., Ribi E., Cantrell J.L. Isolation of a nontoxic lipid A fraction containing tumor regression activity. Cancer Res. 1981, 41:2654-2660.
188. Tamura S., Funato H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur. J. Immunol. 1991, 21:1337-1344.
189. Tamura S., Funato H., Nagamine T., Aizawa C., Kurata T. Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine 1989, 7:503-505.
190. Tamura S., Ishihara K., Miyata K., Aizawa C., Kurata T. Mechanism of enhancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of holotoxin. Vaccine 1995, 13:339-341.
191. Tamura S., Miyata K., Matsuo K., Asanuma H., Takahashi H., Nakajima K., Suzuki Y., Aizawa C., Kurata T. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 1996, 156:3892-3900.
192. Tamura S., Samegai Y., Kurata H., Nagamine T., Aizawa C., Kurata T. Protection against influenza virus infection by vaccine inoculated intransally with cholera toxin B subunit. Vaccine 1988, 6:409-413.
193. Tamura S., Shoji Y., Hasiguchi K., Aizawa C., Kurata T. Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin. Vaccine 1994, 12:1238-1240.
194. Tamura S., Yamanaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., Suzuki Y., Nagamine T., Kawahara K., Danbara H. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 1994, 12:419-426.
195. Tamura S.I., Tanaka H., Takayama R., Sato H., Sato Y., Uchida N. Break of unresponsiveness of delayed-type hypersen-sitivity to sheep red blood cells by pertussis toxin. Cell. Immunol. 1985, 92:376-382.
196. Thapar M.A., Parr E.L., Bozzola J.J., Parr M.B. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine 1991, 9:129-133.
197. Thapar M.A., Parr E.L., Parr M.B. The effect of adjuvants on antibody titers in mouse vaginal fluid after intravaginal immunization. J. Reprod. Immunol. 1990, 17:207.
198. Thomas W.D., Zhang Z., Lei W., Torres J.F., Monath T.P. New mucosal adjuvants for Helicobacter pylori vaccines. Clin. Immunol. Immunopathol. 1995, 76:S94.
199. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y., Furutani Y., Yano O., Kataoka T., Sudo T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 1984, 72:955-962.
200. Tomasi M., Dertzbaugh M., Hunter H., Elson C. Use of multiple emulsions containing cholera toxin (CT) for mucosal immunization. FASEB J. 1994, 8:A283.
201. Tomasi M., Dertzbaugh M.T., Hearn T.I., Hunter R.L., Elson C.O. Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization. Eur. J. Immunol. 1997, 27:2720-2725.
202. Ulrich J.T., Cantrell J.L., Gustafson G.L., K.R.M., Rudbach J.A., Hiernaux J.R. The adjuvant activity of monophosphoryl lipid A. Topics in Vaccine Adjuvant Research 1991, 133-143. CRC Press, Boca Raton, FL.
203. Vajdy M.m, Lycke N. Stimulation of antigen-specific T- and B-cell memory in local as well as systemic lymphoid tissues following oral immunization with cholera toxin adjuvant. Immunology 1993, 80:197-203.
204. Vajdy M., Kosco-Vilbois M.H., Kopf M., Kohler G., Lycke N. Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med. 1995, 181:41-53.
205. Van der Heijden P.J., Bianchi A.T., Dol M., Pals J.W., Stok W., Bokhout B.A. Manipulation of intestinal immune responses against ovalbumin by cholera toxin and its B subunit in mice. Immunology 1991, 72:89-93.
206. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.W. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 2000, 165:4778-4782.
207. van Heyningen S. The ring on a finger. Nature 1991, 351:351.
208. Verheul A.F.M., Versteeg A., DeReuver M.J., Jansze M., Snippe H. Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates. Infect. Immun. 1989, 57:1078-1083.
209. Waksman B.H. Adjuvants and immune regulation by lymphoid cells. Springer Sem. Immunopathol. 1979, 2:5-33.
210. Walsh E.E. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine 1993, 11:1135-1138.
211. Warren H.S., Vogel F.R., Chedid L.A. Current status of immunological adjuvants. Annu. Rev. Immunol. 1986, 4:369-388.
212. Weiner H.L., Friedman A., Miller A., Khoury S.J., al-Sabbagh A., Santos L., Sayegh M., Nussenblatt R.B., Trentham D.E., Hafler D.A. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 1994, 12:809-837.
213. Williamson E., Westrich G.M., Viney J.L. Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. 1999, 163:3668-3675.
214. Wilson A.D., Bailey M., Williams N.A., Stokes C.R. The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin as an adjuvant. Eur. J. Immunol. 1991, 21:2333-2339.
215. Wilson A.D., Clarke C.J., Stokes C.R. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scand. J. Immunol. 1990, 31:443-451.
216. Woogen S.D., Ealding W., Elson C.O. Inhibition of murine lymphocyte proliferation by the B subunit of cholera toxin. J. Immunol. 1987, 139:3764-3770.
217. Woogen S.D., Turo K., Dieleman L.A., Beagley K.W., Elson C.O. Inhibition of murine T cell activation by cholera toxin B subunit is not mediated through the phosphatidylinositol second messenger system. J. Immunol. 1993, 150:3274-3283.
218. Wu H.Y., Russell M.W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 1993, 61:314-322.
219. Wu H.Y., Russell M.W. Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit, and effects of pre-existing anti-CT immunity. Vaccine 1994, 12:215-222.
220. Xu-Amano J., Jackson R.J., Staats H.F., Fujihashi K., Kiyono H., Burrows P.D., Elson C.O., Pillai S., McGhee J.R. Helper T cell subsets for IgA responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa-associated tissues. J. Exp. Med. 1993, 178:1309-1320.
221. Yamamoto S., Yamamoto T., Shimada S., Kuramoto E., Yano O., Kataoka T., Tokunaga T. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol. Immunol. 1992, 36:983-997.
222. Yamamoto M., McGhee J.R., Hagiwara Y., Otake S., Kiyono H. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand. J. Immunol. 2001, 53:211-217.
223. Zhang T., Li E., Stanley S.L. Oral immunization with the dodecapeptide repeat of the serine-rich Entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response. Infect. Immun. 1995, 63:1349-1355.
224. Zigterman G.J., Snippe H., Jansze M., Willers J.M. Adjuvant effects of nonionic block polymer surfactants on liposome-induced humoral immune response. J. Immunol. 1987, 138:220-225.